PharMerica upgraded

|About: PharMerica Corporation (PMC)|By:, SA News Editor

Credit Suisse upgrades PharMerica (PMC) to Outperform and raises its price target from $19 to $30.

Analyst Glen Santangelo cites the company's accelerating growth profile as the main reason for his bullish outlook.

Consensus estimates for 2014 and 2015 are $1.47/share on revenues of $1.68B and $1.75/share on revenues of $1.72B, respectively.

282 mutual funds have positions.